Q1 2024 revenue increased 74% over Q1 2023 to $73 million
Q1 2024 total test reports increased 40% over Q1 2023
Raising full-year 2024 revenue guidance to $255-265 million from $235-240.
Castle Biosciences Reports First Quarter 2024 Results wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.
Presentations at EADO Highlight Potential Impact of Castle Biosciences DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
If choosing to use a molecular test to rule-out a sentinel lymph node biopsy in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes;.
Castle Biosciences Inc : Presentations at EADO Highlight Potential Impact of Castle Biosciences DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.